Skip to main contentSkip to navigation
Ovarian Cancer Research Alliance
Research Exchange
Donate

Investigator

Sho Fujisawa

Memorial Sloan Kettering Cancer Center

SFSho Fujisawa
Papers(1)
Identification of rec…
Collaborators(9)
Thais BasiliZhen SunCatarina SilveiraEdaise M. da SilvaHiginio DopesoJorge S Reis‐FilhoKristian HelinLorenzo FerrandoRodrigo Gularte-Mérida
Institutions(2)
Memorial Sloan Ketter…University Of Copenha…

Papers

Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary

AbstractSclerosing stromal tumor (SST) of the ovary is a rare type of sex cord-stromal tumor (SCST), whose genetic underpinning is currently unknown. Here, using whole-exome, targeted capture and RNA-sequencing, we report recurrent FHL2-GLI2 fusion genes in 65% (17/26) of SSTs and other GLI2 rearrangements in additional 15% (4/26) SSTs, none of which are detected in other types of SCSTs (n = 48) or common cancer types (n = 9,950). The FHL2-GLI2 fusions result in transcriptomic activation of the Sonic Hedgehog (SHH) pathway in SSTs. Expression of the FHL2-GLI2 fusion in vitro leads to the acquisition of phenotypic characteristics of SSTs, increased proliferation, migration and colony formation, and SHH pathway activation. Targeted inhibition of the SHH pathway results in reversal of these oncogenic properties, indicating its role in the pathogenesis of SSTs. Our results demonstrate that the FHL2-GLI2 fusion is likely the oncogenic driver of SSTs, defining a genotypic–phenotypic correlation in ovarian neoplasms.

1Papers
9Collaborators
Links & IDs
0000-0002-5872-5624
Ovarian Cancer Research Alliance

A global leader in the fight against gynecologic cancer

LIVING LAB
Join the Living LabOur TeamGovernance & EthicsSocial Media Toolkit
DISCOVERY LAB
Discovery LabHow It WorksUpcoming WebinarsContribute Data
ABOUT
About OCRAGet InvolvedMake a DonationContact Us

© 2025 Ovarian Cancer Research Alliance, Inc.

PrivacyTermsAccessibility